|
|
 Previous Article | Table of Contents | Next Article 
Detection of minimal residual disease by polymerase chain reaction in
Philadelphia chromosome-positive chronic myelogenous leukemia following
interferon therapy
MS Lee, H Kantarjian, M Talpaz, EJ Freireich, A Deisseroth, JM Trujillo and SA Stass
Department of Hematology, University of Texas, M.D. Anderson Cancer Center,
Houston 77030.
The significance of the polymerase chain reaction (PCR) in the detection of
minimal residual disease in Philadelphia chromosome (Ph')- positive chronic
myelogenous leukemia (CML) following interferon therapy was investigated.
Forty remission blood samples obtained at various remission time points
from 29 patients in complete cytogenetic remission were analyzed. All 40
samples showed minimal residual Ph'- positive cells by PCR: 22 in remission
for less than 12 months, 12 in remission for 12 to 24 months, four in
remission for 25 to 60 months, and two in remission for more than 60
months. Of these 29 patients, seven relapsed at 4, 6, 9, 14, 17, 19, and 50
months after their first PCR-positivity during remission. One developed
extramedullary myelopoiesis at 49 months after PCR-positivity. The
remaining 21 patients remained in complete hematologic and cytogenetic
remission with median follow-up of 13 months (range, 4 to 36 months) after
PCR analysis. These findings indicate that PCR-positivity is not associated
with immediate disease recurrence. Long-term follow-up is essential to
determine the relevance of PCR-positivity, since late recurrence is
observed in our study.
Volume 79,
Issue 8,
pp. 1920-1923,
04/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. G. Jurcic, S. D. Nimer, D. A. Scheinberg, T. DeBlasio, R. P. Warrell Jr, and W. H. Miller Jr
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
Blood,
November 1, 2001;
98(9):
2651 - 2656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hochhaus, A. Reiter, S. S.{b.}e. A. Reichert, M. Emig, J. Kaeda, B. Schultheis, U. Berger, P. C. A. Shepherd, N. C. Allan, R. Hehlmann, et al.
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission
Blood,
January 1, 2000;
95(1):
62 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Monitoring Treatment and Survival in Chronic Myeloid Leukemia
J. Clin. Oncol.,
June 1, 1999;
17(6):
1858 - 1858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Italian Cooperative Study Group on Chronic Mye
Long-Term Follow-Up of the Italian Trial of Interferon-alpha Versus Conventional Chemotherapy in Chronic Myeloid Leukemia
Blood,
September 1, 1998;
92(5):
1541 - 1548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Selleri, T. Sato, L. Del Vecchio, L. Luciano, A. J. Barrett, B. Rotoli, N. S. Young, and J. P. Maciejewski
Involvement of Fas-Mediated Apoptosis in the Inhibitory Effects of Interferon-alpha in Chronic Myelogenous Leukemia
Blood,
February 1, 1997;
89(3):
957 - 964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
